2024
Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2019
Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPD-L1 expression testingFirst-line therapyNon-small cell lung cancerPD-L1 expressionPD-L1 testingCell lung cancerLung cancerFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCell death ligand 1 (PD-L1) expressionFDA approvalDeath ligand 1 (PD-L1) expressionReal-world practice patternsFirst-line treatmentLigand 1 expressionProportion of patientsMonths of diagnosisReal-world careMultivariable logistic regressionCommunity oncology practicesCompanion diagnostic testingExpression testingIdentifiable driver mutationsLine treatment
2018
Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence
Zhou Y, Abel G, Hamilton W, Pritchard-Jones K, Gross C, Walter F, Renzi C, Johnson S, McPhail S, Elliss-Brookes L, Lyratzopoulos G. Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence. Journal Of Global Oncology 2018, 4: 48s-48s. DOI: 10.1200/jgo.18.45300.Peer-Reviewed Original ResearchEmergency presentationDiagnosis of cancerProportion of patientsPatient-reported outcomesPopulation-based studyHealth care useHealth care factorsHealth care interventionsPatient characteristicsPatient's symptomsLung cancerCurrent evidencePatientsDifferent tumorsCancerCancer typesLimited evidenceDiagnosisCancer diagnosisPublic healthPresentationSymptomsSuch presentationsConsistent inequalitiesRelevant evidenceAdherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.
Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2018, 16: 526-534. PMID: 29752327, DOI: 10.6004/jnccn.2018.7001.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsBreast cancerDecreased likelihoodDefinitive breast cancer surgeryLikelihood of mammographySurvivorship care guidelinesCurative-intent treatmentProportion of patientsNonmetastatic breast cancerResidual breast tissueBreast cancer surgeryAdministrative claims dataBreast imagingBreast cancer treatmentMedicare Advantage beneficiariesBreast surveillanceInsured cohortPatient characteristicsAnnual mammographyCancer surgeryCare guidelinesBreast surgeryHealthcare useBlack race
2017
Mammography use in breast cancer survivors: An administrative claims study.
Ruddy K, Sangaralingham L, Neuman H, Greenberg C, Freedman R, Jemal A, Mougalian S, Hunt K, Haddad T, Lemaine V, Ghosh K, Hieken T, Vachon C, Gross C, Shah N. Mammography use in breast cancer survivors: An administrative claims study. Journal Of Clinical Oncology 2017, 35: 6531-6531. DOI: 10.1200/jco.2017.35.15_suppl.6531.Peer-Reviewed Original ResearchBreast cancer survivorsResidual breast tissueCancer survivorsMammography useBreast surgeryBreast cancerEarly-stage breast cancerMetastatic breast cancer diagnosisBreast tissueAnnual surveillance mammographyDefinitive breast surgeryOperable breast cancerCancer diagnosisCommercial insurance databaseProportion of patientsYear of diagnosisMultivariable logistic regressionStage breast cancerAdministrative claims dataYears of ageFirst yearBreast cancer diagnosisInsured cohortUnderwent mammographyRecurrent disease